Kura Oncology stock heads into October 13 webcast focus on KO-7246

Published on 10/08/2026 at 03:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kura Oncology stock posted Q2 revenue of USD 20.87 million and an adjusted loss of USD 0.77 per share. Analysts listed a USD 25.69 consensus target.

KURA, US50127T1097, Illustration mit AI erstellt.

Kura Oncology stock was last at USD 10.67 on Nasdaq on October 7, 2026, after a 1.33 percent gain during the session. The company has scheduled an October 13 webcast on Caspian Therapeutics and its KO-7246 diabetes program, giving investors a near-term checkpoint for a business that now combines commercial oncology with new metabolic research.

Webcast puts Caspian in view

According to GlobeNewswire on October 7, 2026, Kura and Caspian will hold the investor webcast on October 13 at 4:30 p.m. ET. Management plans to discuss Caspian's formation and review KO-7246 data presented at the European Association for the Study of Diabetes meeting.

KO-7246 remains in IND-enabling development, so the event is an early development milestone rather than a commercial launch. Kura developed the program through more than a decade of menin-inhibitor research, while Caspian is pursuing diabetes and other cardiometabolic applications.

Revenue beats the Q2 estimate

Kura reported USD 20.87 million of Q2 2026 revenue, up from the USD 20.16 million consensus estimate, while adjusted loss per share was USD 0.77 versus a USD 0.88 consensus loss, according to MarketBeat in its October 7, 2026 report. The revenue beat was USD 0.71 million, while the adjusted loss was USD 0.11 narrower than expected.

The operating picture still carries a cash-burn tradeoff. Kura's Q2 2026 operating cash flow was negative USD 62.549 million, and cash stood at USD 70.242 million at June 30, 2026.

Analyst target stays far higher

MarketBeat reported on October 7, 2026 that 13 analysts rated Kura, including 11 Buys, one Hold and one Sell. The consensus label was Moderate Buy with an average target of USD 25.69, which lies 140.9 percent above the October 7 price of USD 10.67.

JPMorgan had initiated coverage with an Overweight rating and a USD 30.00 target on October 1, 2026, according to MarketBeat. The spread between the stock and analyst targets reflects the market's dependence on execution from KOMZIFTI and Kura's development pipeline.

Stock remains below yearly high

KURA traded between USD 10.35 and USD 10.99 on Nasdaq on October 7, 2026, with volume of 1,098,728 shares. Its USD 10.67 price was 23.2 percent below the 52-week high of USD 13.90 and above the USD 7.36 low, while market capitalization stood at USD 947.2 million.